ArticleCurrent microbiology2026
In Vitro Anti-infective Efficacy of Green Coffee Bean Extract against Multidrug-resistant Bacteria and in Silico Analysis for Drug-like Properties of Bioactive Compounds.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a significant global health threat, further intensified by multidrug-resistant (MDR) bacteria, necessitating the development of alternative therapies, including the utilization of natural products. This study evaluates the anti-infective potential of green coffee bean extract and the drug-likeness of its bioactive compounds, using a combination of experimental and computational approaches to offer novel multi-target therapeutic potential against MDR pathogens. Methanolic extracts of green and roasted beans of Coffea arabica and Coffea canephora were tested against nine bacteria using the agar-well diffusion method. The highest growth inhibition (22 mm) was observed with green C. arabica. The minimum inhibitory concentration (MIC) of the active extract was lowest against Escherichia coli ATCC 25,922 (62.5 µg/mL), followed by 125 µg/mL against Staphylococcus aureus MTCC 737 and other isolates, whereas higher MICs were observed for Klebsiella pneumoniae ATCC BAA-1705 and Pseudomonas aeruginosa (PAO1), 250 µg/mL and 500 µg/mL, respectively. Biofilm inhibition by the crystal violet assay showed the highest inhibition against E. coli (56.6%), followed by S. aureus (42.3%) and S. marcescens (41.1%), and other strains, whereas a relatively low level of inhibition was recorded against K. pneumoniae and P. aeruginosa (PAO1) at their respective MIC/2 concentrations. Phytochemical analysis revealed the presence of alkaloids, flavonoids, phenols, and tannins, corroborated by FTIR, while GC-MS identified quinic acid and caffeine as the major constituents. ADMET profiling supported the pharmacological potential of key compounds, with minor toxicity concerns. Molecular docking and molecular dynamics simulations of bioactive compounds (ligand) revealed strong interactions with virulent proteins. The cumulative in vitro and in silico findings highlight green coffee bean extract as a promising natural candidate for treating MDR- biofilm-associated infections.
Indexed as
Identifiers
42436253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.